ACADIA Pharmaceuticals Inc.
ACAD
$27.44
$0.893.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.27% | 9.34% | 18.70% | 12.36% | 18.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.27% | 9.34% | 18.70% | 12.36% | 18.28% |
| Cost of Revenue | 28.10% | 4.47% | 19.40% | 44.78% | -50.19% |
| Gross Profit | 2.56% | 12.46% | 18.23% | -6.38% | 311.17% |
| SG&A Expenses | 0.08% | 14.05% | 17.02% | 16.70% | 36.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.03% | 9.77% | 18.05% | 28.82% | -18.82% |
| Operating Income | 12.99% | 6.36% | 26.82% | -80.00% | 154.77% |
| Income Before Tax | 14.92% | 8.15% | 32.27% | 305.73% | 174.42% |
| Income Tax Expenses | -549.99% | 257.11% | 97.71% | 384.59% | -53.65% |
| Earnings from Continuing Operations | 119.07% | -20.14% | 14.69% | 213.87% | 150.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.07% | -20.14% | 14.69% | 213.87% | 150.27% |
| EBIT | 12.99% | 6.36% | 26.82% | -80.00% | 154.77% |
| EBITDA | 13.13% | 6.97% | 7.25% | -66.64% | 161.04% |
| EPS Basic | 115.35% | -21.22% | 13.23% | 210.58% | 149.75% |
| Normalized Basic EPS | 13.00% | 6.62% | 30.61% | -58.31% | 173.64% |
| EPS Diluted | 112.77% | -20.55% | 10.00% | 213.27% | 149.35% |
| Normalized Diluted EPS | 11.85% | 6.58% | 31.35% | -57.94% | 173.59% |
| Average Basic Shares Outstanding | 1.72% | 1.37% | 1.22% | 1.05% | 1.06% |
| Average Diluted Shares Outstanding | 2.69% | 1.51% | 0.63% | 0.11% | 1.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |